Abstract
Impairment in instrumental activities of daily living (IADL) is an early clinical feature of Alzheimer's disease (AD). The neurobiology underlying IADL disruptions is still unclear. We aimed to investigate the relationship between IADL functioning and cortical atrophy across the AD spectrum. We selected 162 memory-clinic subjects with subjective cognitive decline (n = 49), mild cognitive impairment (n = 26) or AD dementia (n = 87), and an available structural MRI acquired at 3.0 Tesla and Amsterdam IADL Questionnaire (A-IADL-Q) assessment. We used linear regression correcting for age, sex, education, vascular injuries, and total intracranial volume to investigate the association between gray matter volume and A-IADL-Q score, and voxel-based morphometry to investigate whether any associations were specific for distinct regions. Less gray matter volume was associated with lower A-IADL-Q scores (β = 0.346, 95% CI = [0.185-0.507], p < 0.001), specifically in cortical regions covering the medial temporal lobes, cingulate cortex, and precuneus (all p(familywise error–corrected) < 0.05). Results were similar when repeating the analyses in amyloid-positive subjects (n = 78). Our findings illustrate that the A-IADL-Q detects functional impairment related to AD-specific neurodegeneration.
Original language | English |
---|---|
Pages (from-to) | 109-116 |
Number of pages | 8 |
Journal | Neurobiology of Aging |
Volume | 75 |
DOIs | |
Publication status | Published - 1 Mar 2019 |
Funding
RJJ, ED, and LV report no disclosures. FB serves as a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer-Schering, Merck Serono, Roche, Novartis, Genzume, and Sanofi-Aventis. FB has received sponsoring from EU-H2020, NWO, SMSR, TEVA, Novartis, Toshiba, IMI, and is supported by the NIHR UCLH Biomedical Research Centre . PS has acquired grant support (for the institution) from GE Healthcare and Piramal. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Novartis, Probiodrug, Biogen, Roche, and EIP Pharma, LLC. BMT receives grant support from Zon-MW. SAMS is supported by grants from JPND and Zon-MW, and has provided consultancy services in the past 2 years for Nutricia and Takeda. All funds were paid to her institution. Research of the Alzhe is part of the neurodegeneration research program of Amsterdam Neuroscience. The VUmc Alzheimer Center is supported by Alzheimer Nederland and Stichting VUmc Fonds . The development of the Amsterdam IADL Questionnaire is supported by grants from Stichting VUmc Fonds and Innovatiefonds Zorgverzekeraars . The present study is supported by a grant from Memorabel (grant no. 733050205 ), which is the research program of the Dutch Deltaplan for Dementia. The Amsterdam IADL Questionnaire is free for use in all public health and not-for-profit agencies and can be obtained via https://www.alzheimercentrum.nl/professionals/amsterdam-iadl .
Funders | Funder number |
---|---|
Alzheimer Nederland and Stichting VUmc Fonds | |
Dutch Deltaplan for Dementia | |
Innovatiefonds Zorgverzekeraars | 733050205 |
Innovatiefonds Zorgverzekeraars |
Keywords
- Alzheimer's disease
- Atrophy
- Dementia
- Instrumental activities of daily living
- Neurodegeneration